Dr. Lara Hathout
Claim this profileRutgers Cancer Institute of New Jersey
Studies Prostate Cancer
Studies Prostate Adenocarcinoma
5 reported clinical trials
23 drugs studied
Affiliated Hospitals
Clinical Trials Lara Hathout is currently running
Stereotactic Radiation + Immunotherapy
for Kidney Cancer
This phase II trial tests whether the addition of radiation to the primary tumor, typically given with stereotactic ablative radiation therapy (SABR), in combination with standard of care immunotherapy improves outcomes in patients with renal cell cancer that is not recommended for surgery and has spread to other places in the body (metastatic). Radiation therapy uses high energy photons to kill tumor cells and shrink tumors. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses of radiation over a shorter period and cause less damage to normal tissue. Immunotherapy with monoclonal antibodies, such as nivolumab, ipilimumab, avelumab, and pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Axitinib, cabozantinib, and lenvatinib are in a class of medications called antiangiogenic agents. They work by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving SABR in combination with standard of care immunotherapy may help shrink or stabilize the cancer in patients with renal cell cancer.
Recruiting1 award Phase 221 criteria
Radiation Therapy
for Prostate Cancer
This phase II trial compares high-dose rate brachytherapy and stereotactic ablative radiotherapy as monotherapy in treating patients with prostate cancer that has not spread to other parts of the body (localized). High-dose rate brachytherapy delivers radiation directly into the prostate within a few minutes by a single radioactive seed through temporarily placed plastic catheters inside the prostate gland. Stereotactic ablative radiotherapy is an external beam radiation method that delivers large doses of radiation to the cancer in a short period of time, usually 5 treatments. This trial aims to find which of these two approaches is better in terms of patient-reported quality of life.
Recruiting1 award Phase 213 criteria
More about Lara Hathout
Clinical Trial Related2 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Lara Hathout has experience with
- Stereotactic Ablative Radiotherapy
- Apalutamide
- High-Dose Rate Brachytherapy
- Triapine
- Cisplatin
- Degarelix
Breakdown of trials Lara Hathout has run
Prostate Cancer
Prostate Adenocarcinoma
Cancer
Adenocarcinoma
Cervical Adenocarcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Lara Hathout specialize in?
Lara Hathout focuses on Prostate Cancer and Prostate Adenocarcinoma. In particular, much of their work with Prostate Cancer has involved treating patients, or patients who are undergoing treatment.
Is Lara Hathout currently recruiting for clinical trials?
Yes, Lara Hathout is currently recruiting for 4 clinical trials in New Brunswick New Jersey. If you're interested in participating, you should apply.
Are there any treatments that Lara Hathout has studied deeply?
Yes, Lara Hathout has studied treatments such as Stereotactic Ablative Radiotherapy, Apalutamide, High-Dose Rate Brachytherapy.
What is the best way to schedule an appointment with Lara Hathout?
Apply for one of the trials that Lara Hathout is conducting.
What is the office address of Lara Hathout?
The office of Lara Hathout is located at: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey 08903 United States. This is the address for their practice at the Rutgers Cancer Institute of New Jersey.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.